Sickle Cell Disease Enrollment Form



Phone: 1-888-280-1190

Fax Referral To: 1-855-297-1270 Phone: 1 Address: 280 Avenida Jesus T. Pinero Ste B Rio Piedras, PR 00927 NCPDP: 4026325

PATIENT INFORMA	TION (Complete or include demograp	hic sheet)			
Patient Name:	DOB:	•			
	City, State, ZIP Code:				
Note: Carrier charges may apply. By p and/or text messages from CVS Spec If unable to contact via text or email, S	Phone (to primary # provided below) Text (to providing the phone number(s) and email address a sialty® about your prescription(s), account, and heal specialty Pharmacy will attempt to contact by phone	bove, you are consenti Ith care. Standard data e.	ing to receive automated calls, emails rates apply. Message frequency varies.		
Email:	Last Four of SSN:	Primary L	anguage:		
Parent/Caregiver/Legal Guard	dian Name (Last, First):	Relationshi	p to patient:		
2 PRESCRIBER INFOI Prescriber's Name: State License #:	NPI #:		 DFA #·		
Prescriber's Name:					
		D	DEA #:		
Group or Hospital:					
	City, State, ZIP Code:				
	Fax: Contact's P				
_	RMATION Please fax copy of prescription at				
4 DIAGNOSIS AND C	LINICAL INFORMATION Ship to: Patient Office	ີໄ Other:			
Diagnosis (ICD-10):					
	Other Code: Des	scription			
Patient Clinical Information:		, o p			
		Height: in/c	em Weight: lh/kg		
Nursing: (for Adakveo)					
 -	nate home health nursing? 🗌 Yes 🔲 No	o Port?	Yes □ No		
	Infusion Clinic Outpatient Health				
Site of Care. Nip office	minusion curic Curpatient fleath	HOLLE HILUSION	J Oti 161		

		ease Complete Patient and I				
		Patient DOB:Patient Phone				
-	iber Name: Prescriber Phone:					
PRESCRI	PTION INFORMA	TION				
MEDICATION	STRENGTH	DOSE &	DIRECTIONS	QUANTITY/REFILLS		
Adakveo	100 mg/10 ml single dose vial		travenously in normal saline (for total es on week 0, week 2 and every 4	Quantity: 1-month supply 3-month supply 12-month supply Refills:		
☐ Endari	5-gram packet	Take grams orally twice per day. Mix Endari powder immediately before ingestion with 8 ounces of cold or room temperature beverage or 4-6 ounces of food.		Quantity: 1-month supply 3-month supply 12-month supply Refills:		
Oxbryta	500 mg tablets	Take 1500 mg orally once daily Other:		Quantity: 1-month supply 3-month supply 12-month supply Refills:		
☐ Oxbryta	300 mg tablets for oral suspension	Take mg orally once daily. Patient weight: Disperse tablets in room temperature, clear liquid before swallowing. Follow additional information provided for oral suspension. Do not swallow whole, cut, crush or chew tablets for oral suspension.		Quantity: 1-month supply 3-month supply 12-month supply Refills:		
Patient is interested	in patient support programs	STAMP SIGNATURE NOT A	ALLOWED Ancillary supplies and kits p	rovided as needed for administra		
		IONATURE REQUIRES (C)		WED)		
"Di A - M. "			TAMP SIGNATURE NOT ALLO	WED)		
"Dispense As Written" / Brand Medically Necessary DAW / May Not Substitute Prescriber's Signature:			May Substitute / Product Selection Permitted / Substitution Permissible Prescriber's Signature:	Date:		
			ATTN: New York and Iowa provide			

payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments. Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers

not affiliated with CVS Specialty and/or one of its affiliates.